EAU 2013 - Programme Book - YouMed

Saturday, 16 March
Sponsored Session
18.00 - 19.30 LUTS/BPH and sexual health - Bridging the gap
Brown Hall 1-2 - Level S2
Symposium
Chair: H. Porst, Hamburg (DE)
Welcome and introduction
H. Porst, Hamburg (DE)
Sexual health and male LUTS - Tackling a sensitive issue
F. Giuliano, Garches (FR)
Tadalfil 5mg once daily - Which patients benefit most?
J.J.M.C.H. De La Rosette, Amsterdam (NL)
Discussion
Challenging questions: Tadalafil once-daily in BPH/LUTS - and now?
F. Giuliano, Garches (FR)
H. Porst, Hamburg (DE)
J.J.M.C.H. De La Rosette, Amsterdam (NL)
Wrap-up
H. Porst, Hamburg (DE)
Aims and objectives
The Eli Lilly satellite symposium “LUTS/BPH and Sexual Health – Bridging the Gap” will provide insights into
recent progress been made in the deeper understanding of the pathophysiology of male LUTS, in particular
its strong link to erectile dysfunction and other co-morbidities.
A wealth of evidence has been published on innovative pharmacological approaches for male LUTS, recently
having led to the approval of Tadalafil 5 mg once daily, for the treatment of the signs and symptoms of
benign prostatic hyperplasia in adult males’, in addition to the existing indication for erectile dysfunction.
The faculty will discuss the pathophysiological link of ED and LUTS/BPH, the current spectrum of available
medical treatment options for LUTS/BPH with a particular focus on sexual quality of life and will define their
position on the expected role of Tadalafil 5 mg once daily in the current treatment algorithm for male LUTS.
Sponsored by ELI LILLY AND COMPANY
EAU Milan 2013
403
Sponsored Sessions